Tags : Systolic Heart Failure

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension

Vartika Singh March 18, 2019

Shots: The PIONEER-HF 4-week extension study involves assessing Entresto vs Enalapril in ~832 patients with systolic heart failure treated with Entresto for the first 8 wks.& the last 4wks and […]readmore

Tags : Systolic Heart Failure

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Systolic Heart Failure

﻿Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Novartis Reports Results of Entresto (sacubitril/valsartan) in PIONEER-HF 4-Week Extension